French researchers have created artificial skin in a laboratory designed for immediate grafting without collecting cells from the patient. Announced on November 20, 2026, by a public-private consortium that includes Urgo, the development is described by the company as a world first. It must still prove itself in clinical trials, scheduled to begin in 2030.
The goal is to give surgeons universal skin manufactured in advance and available to treat severe wounds, particularly in patients with extensive burns. Stored at −150°C, it could be thawed and used directly in the operating room. Commercialization, however, remains a target for around 2040, following a shift to industrial-scale production.
“We started with human cells,” said Guillaume Olive, Urgo’s managing director responsible for research, development and innovation. He said the selected cellular technologies are intended to prevent rejection and allow the graft to take immediately. That claimed compatibility is central to the project; clinical trials must still establish how the skin performs in patients.
Alongside wound-care specialist Urgo, the consortium brings together the CNRS, Lyon 1 University, the Center for the Study of Stem Cells, the French Blood Establishment and Dassault Systèmes. After five years of research, the teams can manufacture about 100 units of the skin.
For patients with severe burns, the aim is to eliminate the need for autografting, currently the most widely used surgical technique: healthy skin is taken from the patient and placed over burned areas. Urgo Group President Guirec Le Lous said treatment can last several months. He sees advance production as a way eventually to provide surgeons with unlimited quantities of skin grafts, without depending on tissue collected from the patient.
The clinical study is scheduled to start in 2030 at the French Blood Establishment’s pharmaceutical facilities. The invention’s cost is estimated at €100 million, funded by the company, local and regional authorities, and the French state.
The laboratory result opens a specific possibility: keeping a supply of ready-to-use skin rather than having to harvest the patient’s own. Between the roughly 100 units the teams can currently produce and the unlimited supply they envision stand the clinical and industrial stages still to come.


